1.1,2) These investigations provided information concerning the antibiotic properties of cycloserine analogues, but they did not determine whether these derivatives interacted with alanine racemase since most cell growth studies do not monitor substrate cellular uptake, efflux and metabolism. In this study, we take advantage of new methodologies for protein expression3,4) to examine the importance of the N(2)-structural site in cycloserine for bioactivity. This position has been largely overlooked in earlier investigations.1,2) The biochemical properties of eighteen N(2)-modified cycloserine derivatives were tested against alanine racemases from Escherichia coli, Staphylococcus aureus, and Mycobacterium tuberculosis, and then evaluated in growth assays using E. coli and S. aureus. We found that N(2)-modification in D,L-cycloserine led to loss of enzymatic inhibitory activity and that the loss of drug function was not enzyme specific. These findings are explained in context of a recently proposed mechanisms for inactivation of PLP-dependent enzymes by cycloserine.7,8) Results and Discussion
Selection of Compounds
The parent compound in our study is D,L-cycloserine (1).
We modified only the N(2) ring position in 1. The eighteen compounds (2-19) selected for evaluation are listed in Table 1 . We varied the size and electronic properties of the N(2) amino substituent. Included in our list were N(2) amino moieties that can enter into hydrogen bonding interactions with amino acid residues that comprise the alanine racemase PLP binding pocket. In all cases, the compounds were prepared as the N(2)-modified cycloserine racemate. This choice permitted our use of synthetic methods for 2-19 known to racemize 1. (Tables 2 and 3 ). In the case of 32 and 33, the diastereomeric mixture obtained after N(2) alkylation was separated by PTLC and then the Cbzgroup was removed (10% Pd-C, H2) and the product converted to the racemic 13 and 14 hydrochloride salts. We did not identify the stereochemical identity of the N(2) substituent in 13 and 14.
Biochemical and Biological Properties
The inhibitory activities14) of D,L-cycloserine derivatives 2-19 were evaluated against purified alanine racemases, products of the air gene, from E. coli,5) S. aureus, and M. tubercuiosis5) ( Table 1) . Three enzymes were evaluated since alanine racemases display approximately 50% amino acid identity.15) In our experiments, D,L-1 served as the control. We also determined the antibiotic activity of the D,L-cycloserine analogues against E. coli and S. aureus by establishing their minimal inhibitory concentration (MIC) in a microtiter plate growth assay ( Table 1 ). All of the modifications at the N(2) site resulted in reduced activity in both the enzyme and growth assay. These results. underscore the importance of unsubstituted N(2)-cycloserine modification on drug function. There were three compounds 5, 9 and 16, however, with N (2) substitutions that retained significant, albeit reduced, activity in both assays. For these compounds we determined their kinetic inhibition constant, Ki, for the three alanine racemases (Table 1) . We found that the Ki ranged from 0.36-11.93mM, which was 34-864-fold higher than that observed for 1. Compounds 5, 9 and 16 contained an ether, hydroxyl, and hydroxamate containing side chain, respectively. These side chains could serve as sites for We have learned that selective N(2) modification of cycloserine (1) led to a loss of inhibitory activity compared with 1 against alanine racemases from E. coli, S. aureus, and M. tuberculosis. Cycloserine (1) inhibition has been projected to proceed through the intermediacy of a C(4) amino cycloserine bound PLP aldimine 42. In all our cases we retained the unsubstituted C(4) exocyclic amine necessary for PLP Schiff base formation. Why then do we observe a significant loss for N(2)-substituted cycloserine 41 activity? Recently, the SILVERMAN7) and RINGE8) research groups proposed a novel aromatization mechanism for inactivation of PLP-dependent aminotransferases by 1 MOINI. The low-resolution mass studies were run on a Finnegan MAT-TSQ-70 instrument and the high-resolution mass studies were conducted on a Micromass ZAB-E spectrometer. Thin-layer chromatography was run on Z27428-3). N-Methoxy-2-bromoethanamide16) and Nhydroxy-N-methyl-2-bromoethanamide17) were prepared according to literature procedures. MeOH-CHCl3) to afford the desired product ( Table 2 ).
2-Methylthiomethyl-N-Fmoc-DL-cycloserine (40)
To an anhydrous DME solution (2ml) of 3913) (97mg, 0.30mmol) was added tent-BuOK (34mg, 0.31mmol). Excess acid (HCl, HBF4) was removed in vacuo and the product was precipitated by addition of isopropyl ether. The product was filtered, washed with isopropyl ether, and dried in vacuo to yield the desired product (Table 3) .
2-Methylthiomethyl-DL-cycloserine Hydrochloride (6) To a THE (0.57ml) solution of 40 (29mg, 0.07mmol) warmed to room temperature and then stirred (2.5 hours).
The mixture was concentrated in vacuo to give a residue, which was purified by PTLC (2.5% MeOH-CHCl3) to give the amine. The amine was dissolved in MeOH (0.1ml), and and the product was precipitated by addition of isopropyl ether, and dried to give 6 as a white hygroscopic solid The alanine racemases from the alr genes of M. tuberculosis and E. coli were purified as described from E. coli strains harboring pET expression plasmids pMB1909 and pMB1556, respectively.5) The sequence of the air gene from S. aureus was initially obtained from a genomic sequence provided to us by Schering-Plough. Primers were made, and the gene was amplified and sequenced. The nucleotide sequence is identical with the subsequent GenBank Acc. No. Y16431 entry. Analogous to what was described for M. tuberculosis,5) the gene was cloned in pET26, expressed in E. coli BL21(DE3)pLysS (Novagen, Madison, WI) to make strain MB1978, and the protein was purified to electrophoretic homogeneity using anion exchange chromatography.
Alanine
Racemase Enzyme Assay Alanine racemase activity was measured at room tometric assay.14) The alanine racemase enzymes from S.
were incubated with 100mM Tricine, pH 8.5, 0.08 units Lalanine dehydrogenase (Sigma), 10mM NAD and 2.5mM
inhibitor. After 30 minutes at room temperature, 10mM Dalanine was added and the reaction was monitored in a Beckman spectrophotometer at 340nm for 5 minutes.
Enzyme activity was proportional to the amount of NADH produced in the reaction. Inhibition was expressed as the quotient of enzyme activity without inhibitor over enzyme activity in the presence of inhibitor. All assays were performed in duplicate (Table 1) .
Antimicrobial Growth Assay E. coli and S. aureus were both grown in cation- were filled with MHB without bacteria. Each inhibitor (5mM) was added to the top row of wells of the plate and two-fold serial dilutions were performed down eachcolumn and culture turbidity was monitored using a microplate reader at 560nm. All assays were performed in duplicate (Table 1) . replotted versus inhibitor concentration. The X-intercept of the line that fit these data was then used to calculate the Ki (Table 1 ).
